40 research outputs found
Wastewater Management in Citrus Processing Industries: An Overview of Advantages and Limits
Citrus-processing industries produce large volumes of wastewater (CPWW). The large variability of these volumes coupled to physicochemical characteristics of CPWW determine severe constraints for their disposal due to both economic and environmental factors. To minimize the management costs and prevent the negative ecological impacts of CPWW, several systems have been proposed and adopted. However, all these treatment/valorization routes have many issues that are not yet thoroughly known by the scientific community and stakeholders of the citrus-processing chain. This paper reports an overview of the possible treatment/valorization opportunities for CPWW: intensive biological treatment, lagooning, direct land application, energy conversion, and biorefinery uses for the extraction of added-value compounds. Advantages and constraints are presented and discussed, and the following conclusions are achieved: (i) there is not a unique solution for CPWW treatment, since the best management system of CPWW must be chosen case by case, taking into account the quality/quantity of the effluent and the location of the transformation industry; (ii) the adoption of a biorefinery approach can increase the competitiveness and the further development of the whole citrus sector, but the cost of novel technologies (some of which have not been tested at real scale) still limits their development
Recommended from our members
Advanced Robotic Therapy Integrated Centers (ARTIC): an international collaboration facilitating the application of rehabilitation technologies
Background: The application of rehabilitation robots has grown during the last decade. While meta-analyses have shown beneficial effects of robotic interventions for some patient groups, the evidence is less in others. We established the Advanced Robotic Therapy Integrated Centers (ARTIC) network with the goal of advancing the science and clinical practice of rehabilitation robotics. The investigators hope to exploit variations in practice to learn about current clinical application and outcomes. The aim of this paper is to introduce the ARTIC network to the clinical and research community, present the initial data set and its characteristics and compare the outcome data collected so far with data from prior studies. Methods: ARTIC is a pragmatic observational study of clinical care. The database includes patients with various neurological and gait deficits who used the driven gait orthosis Lokomat® as part of their treatment. Patient characteristics, diagnosis-specific information, and indicators of impairment severity are collected. Core clinical assessments include the 10-Meter Walk Test and the Goal Attainment Scaling. Data from each Lokomat® training session are automatically collected. Results: At time of analysis, the database contained data collected from 595 patients (cerebral palsy: n = 208; stroke: n = 129; spinal cord injury: n = 93; traumatic brain injury: n = 39; and various other diagnoses: n = 126). At onset, average walking speeds were slow. The training intensity increased from the first to the final therapy session and most patients achieved their goals. Conclusions: The characteristics of the patients matched epidemiological data for the target populations. When patient characteristics differed from epidemiological data, this was mainly due to the selection criteria used to assess eligibility for Lokomat® training. While patients included in randomized controlled interventional trials have to fulfill many inclusion and exclusion criteria, the only selection criteria applying to patients in the ARTIC database are those required for use of the Lokomat®. We suggest that the ARTIC network offers an opportunity to investigate the clinical application and effectiveness of rehabilitation technologies for various diagnoses. Due to the standardization of assessments and the use of a common technology, this network could serve as a basis for researchers interested in specific interventional studies expanding beyond the Lokomat®
Sviluppo di sensori MEMS di velocitĂ delle particelle acustiche.
Sensori termici possono essere utilizzati sia per la misura diretta di quantità termiche come calore e temperatura, e sia come trasduttori indiretti per convertire attraverso un effetto termico quantità , quali pressione, velocità di fluidi, velocità di particelle acustiche, in un segnale elettrico. La loro integrazione su un chip di silicio è diventata realizzabile con lo sviluppo di tecniche di micromachining che hanno permesso la fabbricazione di strutture micrometriche termicamente isolati dal substrato. La miniaturizzazione in scala micrometrica è un punto di svolta per ottenere dispositivi che garantiscono vantaggi significativi in termini di consumo di potenza, velocità di risposta e limiti di risoluzione.
Questo lavoro di tesi riguarda lo sviluppo del post-processing necessario per la fabbricazione di sensori MEMS, in particolare flussimetri termici e sensori di velocità delle particelle acustiche (microflown) presenti sul chip progettato e fabbricato secondo il processo BCD6s di STMicroelectronics. Il chip comprende oltre i sensori anche un'interfaccia elettronica configurabile in modo digitale che incorpora funzioni volte a migliorare la precisione e il limite di rilevazione del sensore, attraverso la compensazione dell’offset intrinseco dei sensori e la riduzione della sensibilità alla pressione.
I test effettuati sui sensori, microflown e flussimetri, ottenuti al completamento del post-processing hanno mostrato risultati soddisfacenti.
E’ stata inoltre eseguita una caratterizzazione dettagliata dell'interfaccia elettronica, ottenendo un completo accordo con le specifiche iniziali
Wastewater Management in Citrus Processing Industries: An Overview of Advantages and Limits
Citrus-processing industries produce large volumes of wastewater (CPWW). The large variability of these volumes coupled to physicochemical characteristics of CPWW determine severe constraints for their disposal due to both economic and environmental factors. To minimize the management costs and prevent the negative ecological impacts of CPWW, several systems have been proposed and adopted. However, all these treatment/valorization routes have many issues that are not yet thoroughly known by the scientific community and stakeholders of the citrus-processing chain. This paper reports an overview of the possible treatment/valorization opportunities for CPWW: intensive biological treatment, lagooning, direct land application, energy conversion, and biorefinery uses for the extraction of added-value compounds. Advantages and constraints are presented and discussed, and the following conclusions are achieved: (i) there is not a unique solution for CPWW treatment, since the best management system of CPWW must be chosen case by case, taking into account the quality/quantity of the effluent and the location of the transformation industry; (ii) the adoption of a biorefinery approach can increase the competitiveness and the further development of the whole citrus sector, but the cost of novel technologies (some of which have not been tested at real scale) still limits their development
Binding of FVIIa to TF promotes smooth muscle cell proliferation in vitro via activation of the extracellular regulated kinases
Prevalence of prothrombotic polymorphisms in a selected cohort of cryptogenic and noncryptogenic ischemic stroke patients
Ischemic stroke is a complex multifactorial disease and approximately
30%, especially in the young, are cryptogenic. In some of the patients
with cryptogenic ischemic stroke the underlying risk factor may be a
prothrombotic state. We studied 101 patients with ischemic stroke under
55 years of age. All the patients underwent an extensive diagnostic
evaluation to determine the cause of stroke. Common variations in the
genes encoding factor V, prothrombin, 5,10-methylenetetrahydrofolate
reductase, plasminogen activator inhibitor-1, and human platelet
alloantigens-1 were evaluated. Of the 101 patients with ischemic
stroke, 28 patients had cryptogenic ischemic stroke. At least one of
the different genetic polymorphisms investigated was present in 44%
patients in the total group and in 48% of patients with cryptogenic
ischemic stroke. In this study population under 55 years of age there
was no significant difference in the prevalence of various genetic
polymorphisms, factor V, prothrombin, 5,10-methylenetetrahydrofolate
reductase, plasminogen activator inhibitor-1, and human platelet
alloantigens) in patients with cryptogenic ischemic stroke and in
patients with ischemic stroke of determined cause
Analysis of sarcomeric gene proteins in a child choort enlarges the genetic spectrum of hypertrophic cardiomyopathy.
Binding of FVIIa to TF promotes smooth muscle cell proliferation in vitro via activation of the extracellular regulated kinases
A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiovascular disorder worldwide. It is the leading cause of sudden cardiac-related death in young people and a major cause of cardiac failure and death in elderly people. However, HCM frequently goes undiagnosed until the appearance of overt signs and symptoms, thereby delaying prophylactic and therapeutic measures. We screened patients for sarcomeric genes associated with HCM to obtain information that could be useful for an early diagnosis and so limit the severe consequences of silent HCM. We recruited 39 families with HCM from southern Italy and found mutations in 41% of families (12 with familial HCM and 4 with sporadic HCM). The remaining 23 families (59%) were negative for myofilament gene mutations. Of the 12 mutations identified, 8 were novel. Screening of the other family members available revealed that 27 had mutations; 11 of these individuals had no signs or symptoms suggestive of HCM. This study, besides characterizing the spectrum of mutations in another childhood population, and revealing an even greater genetic heterogeneity than formerly recognized, may increase genotype-phenotype correlations, and thus may help to identify asymptomatic candidates for early preventive or therapeutic measures. © 2009 John Wiley & Sons A/S
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence
A hyperglycemic state, also in non-diabetic subjects, may be associated with acute coronary syndrome (ACS). Aim of this review is to describe the pathophysiologic association between ACS and hyperglycemic state, the protective mechanisms of a tight glycaemic control in ACS on CV outcomes, and the supporting clinical evidence. Several mechanisms may be responsible of a poor CV outcome in subjects with hyperglycemia during ACS. Endothelial NAPDH oxidase-2 (NOX2) activation in response to high glucose alters the balance between Raf/MAPK-dependent vasoconstriction and PI3K/Akt-dependent vasodilation in favour of constriction. Hyperglycaemia induces an overproduction of superoxide by the mitochondrial electron transport chain through different molecular mechanisms. Moreover, hyperglycaemia increases the size of the infarct by causing myocardial cell death through apoptosis and reducing the collateral blood flow. High FFA concentrations lead to toxicity mechanisms in acutely ischemic myocardium. On the other hand, a tight glycaemic control in ACS exerts a cardioprotective action by anti-inflammatory and anti-apoptotic mechanisms, anti-oxidative stress, endothelium protection, FFA reduction, anti-glucotoxic effect, IR and cardiac fuel metabolisms improvement, heart stem cells protection and reduced activation of adrenergic system. Unfortunately, the clinical studies supporting the above pathophysiological background are few and sometimes controversial, more likely due the risk of hypoglycemia linked to the insulin therapy generally used during ACS. Intriguingly, GLP-1 RA and SGLT2i, demonstrated highly effective in the cardiovascular prevention in high-risk subjects without the risk of hypoglycemia, might keep this cardioprotective effect even in acute conditions such as ASC